Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Author-Supplied Keywords:
      CA19-9
      dysplasia
      GPC3
      immunohistochemistry
      KRT19
      Pancreatic ductal adenocarcinoma
      pancreatic intraepithelial neoplasia
    • Abstract:
      OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with metastasis in most patients at diagnosis. The molecular mechanisms associated with its high malignancy have not been fully elucidated. This study investigated the clinicopathological significances of GPC3 and KRT19 expression in PDAC. METHODS: GPC3, KRT19, and CA19-9 protein expression were measured by immunohistochemistry. RESULTS: GPC3 and KRT19 protein levels were overexpressed in PDAC tumors compared to normal pancreatic tissues, benign pancreatic tissues, and peritumoral tissues (P< 0.01). The percentage of positive GPC3 and KRT19 expression were significantly higher in PDAC patients with larger tumor size, poorly differentiated tumor, lymph node metastasis, invasion, and TNM stage III/IV disease than in patients with small tumor size, well-differentiated tumor, no lymph node metastasis and invasion, as well as TNM stage I/II stage disease (P< 0.05 or P< 0.01). Benign pancreatic lesions with positive GPC3 and KRT19 protein expression exhibited dysplasia or intraepithelial neoplasia. Kaplan-Meier survival analysis showed that PDAC patients with positive GPC3 and KRT19 expression survived significantly shorter than patients with negative GPC3 and KRT19 expression (P < 0.05 or P< 0.001). Cox multivariate analysis revealed that positive GPC3 and KRT19 expression were independent poor prognosis factors in PDAC patients. CONCLUSIONS: GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Cancer Biomarkers is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
      2Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
      3Department of Pathology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
      4Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China
    • Full Text Word Count:
      1328
    • ISSN:
      1574-0153
    • Accession Number:
      10.3233/CBM-160655
    • Accession Number:
      131381776
  • Citations
    • ABNT:
      YAO, H. et al. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomarkers, [s. l.], v. 17, n. 4, p. 397–404, 2016. DOI 10.3233/CBM-160655. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=131381776&custid=s8280428. Acesso em: 14 ago. 2020.
    • AMA:
      Yao H, Yang Z, Liu Z, et al. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomarkers. 2016;17(4):397-404. doi:10.3233/CBM-160655
    • APA:
      Yao, H., Yang, Z., Liu, Z., Miao, X., Yang, L., Li, D., Zou, Q., & Yuan, Y. (2016). Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomarkers, 17(4), 397–404. https://doi.org/10.3233/CBM-160655
    • Chicago/Turabian: Author-Date:
      Yao, Hongliang, Zhulin Yang, Ziru Liu, Xiongying Miao, Leping Yang, Daiqiang Li, Qiong Zou, and Yuan Yuan. 2016. “Glypican-3 and KRT19 Are Markers Associating with Metastasis and Poor Prognosis of Pancreatic Ductal Adenocarcinoma.” Cancer Biomarkers 17 (4): 397–404. doi:10.3233/CBM-160655.
    • Harvard:
      Yao, H. et al. (2016) ‘Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma’, Cancer Biomarkers, 17(4), pp. 397–404. doi: 10.3233/CBM-160655.
    • Harvard: Australian:
      Yao, H, Yang, Z, Liu, Z, Miao, X, Yang, L, Li, D, Zou, Q & Yuan, Y 2016, ‘Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma’, Cancer Biomarkers, vol. 17, no. 4, pp. 397–404, viewed 14 August 2020, .
    • MLA:
      Yao, Hongliang, et al. “Glypican-3 and KRT19 Are Markers Associating with Metastasis and Poor Prognosis of Pancreatic Ductal Adenocarcinoma.” Cancer Biomarkers, vol. 17, no. 4, Nov. 2016, pp. 397–404. EBSCOhost, doi:10.3233/CBM-160655.
    • Chicago/Turabian: Humanities:
      Yao, Hongliang, Zhulin Yang, Ziru Liu, Xiongying Miao, Leping Yang, Daiqiang Li, Qiong Zou, and Yuan Yuan. “Glypican-3 and KRT19 Are Markers Associating with Metastasis and Poor Prognosis of Pancreatic Ductal Adenocarcinoma.” Cancer Biomarkers 17, no. 4 (November 22, 2016): 397–404. doi:10.3233/CBM-160655.
    • Vancouver/ICMJE:
      Yao H, Yang Z, Liu Z, Miao X, Yang L, Li D, et al. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomarkers [Internet]. 2016 Nov 22 [cited 2020 Aug 14];17(4):397–404. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=131381776&custid=s8280428